BioNTech SE
NASDAQ:BNTX
BioNTech SE
Operating Income
BioNTech SE
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
BioNTech SE
NASDAQ:BNTX
|
Operating Income
€908m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
MorphoSys AG
XETRA:MOR
|
Operating Income
-€440.4m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
CureVac NV
NASDAQ:CVAC
|
Operating Income
-€269.7m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
Immatics NV
NASDAQ:IMTX
|
Operating Income
-€101.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Operating Income
€120.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
57%
|
CAGR 10-Years
8%
|
|
Formycon AG
XETRA:FYB
|
Operating Income
-€369k
|
CAGR 3-Years
62%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is BioNTech SE's Operating Income?
Operating Income
908m
EUR
Based on the financial report for Dec 31, 2023, BioNTech SE's Operating Income amounts to 908m EUR.
What is BioNTech SE's Operating Income growth rate?
Operating Income CAGR 1Y
-93%
Over the last year, the Operating Income growth was -93%.